ComparaTOX™ HT:

Multi-Tissue, Comparative High-Throughput In Vitro Toxicity Screening 

 

AND 

 

ComparaTOX™ FS:

Full Service In Vitro Comparative Toxicity Testing

 

 HemoGenix® is a Compliant Contract Research Service Supplier through Scientist.com

 

 

 

Although all of our proprietary assays for different tissues and species can be performed using high-throughput technology, our new ComparaTOX™ HT Panels have now been redesigned to test for potential toxicity in the most streamlined and cost-effective manner.

 

  • Test a minimum of 5 compounds on a minimum of 2 tissues.
  • Thereafter, high-throughput screening is available in multiples of 5 compounds; e.g.10, 15, 20 compounds and more.
  • Comparative screening performed only for human tissues (at the present time).
  • Set price for multiples of 5 compounds tested on specific tissues. 
  • Toxicities available for toxicity screening are:
    • Hematotoxicity
    • Immunotoxicity
    • Mesenchymal Cell Toxicity
    • Hepatotoxicity
    • Renal toxicity
    • Cardiotoxicity
    • Skin toxicity
    • Neural toxicity
    • Intestinal toxicity
    • Tumor toxicity
    • Cell line toxicity
  • Tissues available for toxicity screening:
    • Bone marrow (SC-HPP 2, SC-GEMM 1, P-BFU 1, P-GM 1, P-Mk 1, P-Tcell 3, P-Bcell 2)
    • Peripheral blood cells for T- or B-immune cells (Tcell 3, Bcell 2)
    • Mesenchymal cells derived from bone marrow
    • Hepatocytes (iPS-derived or cryopreserved, primary, pooled)
    • Renal mixed, epithelial cells
    • Cardiomyocytes (iPS-derived or cryopreserved primary)
    • Skin fibroblasts
    • iPS-derived neural cells
    • Intestinal epithelial cells
    • Tumor cells (please inquire)
    • Cell lines (please inquire)
  • All assays performed in 384-well plates.
  • All high-thoughput toxicity assays use standardized and validated ATP bioluminescence readout technology, allowing a direct comparison of potential toxicity between tissues.
  • All assays validated according to FDA Bioanalytical Method Validation Guidelines.
  • Where appropriate, IC values provided.
  • Protocol, all raw data and graphical data provided in a single Excel Workbook
  • Fast turnaround time: Usually within 7-14 days or less depending on tissue type.

In contrast to ComparaTOX™ HT, where the cost for determining the response of multiples of 5 compounds screened on specific cell types from different human tissues is a set price with a minimal report, ComparaTOX™ is a full and complete study platform.

  • Any number of compounds can be tested.
  • Available for the same types of tissues provided with ComparaTOX™ HT.
  • Available for a greater variety of cell types.
  • Available for different species (where appropriate).
  • Uses the same standardized and validated ATP bioluminescence technology as ComparaTOX™ HT.
  • ComparaTOX™ is a full-service platform that includes a full report (Draft and Final Report) with QA audit.

Since the development of the ATP bioluminescence, HALO® Platform for in vitro hematotoxicity testing, the same readout technology has been applied to different cell types from multiple tissues that provide the basis for the two ComparaTOX™ Platforms. These assays are as follows: 

We realize that for some small and medium biotechnology and pharamaceutical companies, outsourcing to a contract research laboratory can be expensive.

 

To reduce the costs of toxicity testing, our partner company, Preferred Cell Systems™, provides the same toxicity assays as kits, so that toxicity testing can be performed in-house.

 

However, Preferred Cell Systems™, with few exceptions, does not sell or provide the cells needed for the assay kits. Procuring the cells is the responsibility of the customer. In addition, in some cases, maintenance/growth medium is also not provided, since there are many different formulations for different cell types. 

 

All assay kits employ standardized and validated ATP bioluminescence readout technology. Therefore, to use any of these assay kits, a luminescence plate reader is required.

 

Below are the links to the different toxicity assays on the Preferred Cell Systems™ website.